ciglitazone has been researched along with drf 2725 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chopra, B; Georgopoulos, NT; Hinley, J; Nicholl, A; Oleksiewicz, MB; Southgate, J | 1 |
3 other study(ies) available for ciglitazone and drf 2725
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Topics: Apoptosis; Calcium; Calcium Channels; Caspase 3; Caspase 9; Cell Division; Cells, Cultured; Chromans; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Membrane Potential, Mitochondrial; Oxazines; p38 Mitogen-Activated Protein Kinases; Peroxisome Proliferator-Activated Receptors; Phenoxyacetates; Phenylpropionates; Rosiglitazone; Thiazolidinediones; Troglitazone; Urothelium | 2009 |